Category:
Prophylactic Biological Products
CAS NO:
NA
Standard:
In-house Standards,
A fixed-dose combination antiretroviral therapy comprising Lamivudine, Zidovudine, and Nevirapine. This formulation targets HIV-1 replication via dual nucleoside reverse transcriptase inhibitors and a non-nucleoside inhibitor. The synthesis involves complex chiral resolution and coupling reactions.
Contraindicated in patients with severe hepatic impairment or hypersensitivity to components. Strict storage is required at controlled room temperature (20°C–25°C) away from moisture. Clinical monitoring for hepatotoxicity, lactic acidosis, and skin rashes is mandatory prior to initiation.